Clinical Experience with Cefotaxime in the Treatment of Serious Bone and Joint Infections

LeFrock, Jack L.; Carr, Bernice B.

doi:10.1093/clinids/4.supplement_2.s465

Cited by 21 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In nonrandomized studies of adults with chronic osteomyelitis, 4-6 weeks of parenteral b-lactam antibiotic therapy has cured 60%-90% of cases (Table 3). The varying cure rates may be related to variable diagnostic criteria, use of concomitant surgical debridement (specifically reported in only 2 studies [107,108]), or duration of follow-up. In multiple studies, the cure rates of infections caused by Pseudomonas were lower than those for other pathogens [108,109,112].…”

Section: Parenteral Therapymentioning

confidence: 99%

Systemic Antibiotic Therapy for Chronic Osteomyelitis in Adults

Spellberg

Lipsky

2011

Clinical Infectious Diseases

379

285

View full text Add to dashboard Cite

The standard recommendation for treating chronic osteomyelitis is 6 weeks of parenteral antibiotic therapy. However, oral antibiotics are available that achieve adequate levels in bone, and there are now more published studies of oral than parenteral antibiotic therapy for patients with chronic osteomyelitis. Oral and parenteral therapies achieve similar cure rates; however, oral therapy avoids risks associated with intravenous catheters and is generally less expensive, making it a reasonable choice for osteomyelitis caused by susceptible organisms. Addition of adjunctive rifampin to other antibiotics may improve cure rates. The optimal duration of therapy for chronic osteomyelitis remains uncertain. There is no evidence that antibiotic therapy for >4-6 weeks improves outcomes compared with shorter regimens. In view of concerns about encouraging antibiotic resistance to unnecessarily prolonged treatment, defining the optimal route and duration of antibiotic therapy and the role of surgical debridement in treating chronic osteomyelitis are important, unmet needs.

show abstract

Section: Parenteral Therapymentioning

confidence: 99%

Systemic Antibiotic Therapy for Chronic Osteomyelitis in Adults

Spellberg

Lipsky

2011

Clinical Infectious Diseases

379

285

View full text Add to dashboard Cite

show abstract

“…Meyers et al reported that osteomyelitis due to Gram-negative bacteria represented 28% of all cases of osteomyelitis (20). In one study of 55 patients, 32 had chronic osteomyelitis induced by Gram-positive and/or Gram-negative organisms (14). But there are very few experimental models of osteomyelitis induced by Gram-negative organisms.…”

Section: Discussionmentioning

confidence: 99%

“…Staphylococcus aureus remains the most common causative pathogen for osteomyelitis; however, Gram-negative bacilli are more common in adults with chronic or nosocomially acquired infections (14)(15)(16)(17). In view of the fact that vancomycin and teicoplanin are not active against Gram-negative bacteria, the purpose of this study was to establish a model of osteomyelitis induced by Escherichia coli and to further evaluate the effects of borate glass as a gentamicin carrier on the treatment of osteomyelitis induced by Gram-negative bacteria in rabbits.…”

mentioning

confidence: 99%

Gentamicin-Loaded Borate Bioactive Glass Eradicates Osteomyelitis Due to Escherichia coli in a Rabbit Model

Xie

Cui

Zhao

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The treatment of osteomyelitis induced by Gram-negative bacilli is rarely reported in the literature. This study established a rabbit tibia model of osteomyelitis induced by the Gram-negative bacillus Escherichia coli. Using this model, pellets composed of a chitosan-bonded mixture of borate bioactive glass and gentamicin were evaluated in vitro and in vivo for the treatment of osteomyelitis induced by Escherichia coli. Our results showed that the pellets in phosphate-buffered saline released gentamicin continuously over 26 days. Without the simultaneous use of a systemic antibiotic, the implantation of the gentamicin-loaded pellets into the osteomyelitis region of the tibia resulted in the eradication of 81.82% of infections, as determined by microbiological, histological and radiographic evaluation, and supported the ingrowth of new bone into the tibia defects after 6 weeks of implantation. The results indicate that the gentamicin-loaded borate bioactive glass implant, combining sustained drug release with the ability to support new bone formation, could provide a method for treating osteomyelitis induced by Gram-negative bacilli.

show abstract

Bone and Skin Infections

Aweeka¹

1992

Applied Therapeutics

View full text Add to dashboard Cite

Clinical Experience with Cefotaxime in the Treatment of Serious Bone and Joint Infections

Cited by 21 publications

References 10 publications

Systemic Antibiotic Therapy for Chronic Osteomyelitis in Adults

Systemic Antibiotic Therapy for Chronic Osteomyelitis in Adults

Gentamicin-Loaded Borate Bioactive Glass Eradicates Osteomyelitis Due to Escherichia coli in a Rabbit Model

Bone and Skin Infections

Contact Info

Product

Resources

About